AUS
NZ
UK
CA
USA
IND
Highlights:
Imricor Medical Systems performs its first iCMR ablation procedure at Lausanne University Hospital (CHUV), Switzerland.
CHUV becomes Imricor's first customer site in Switzerland and the third site in the VISABL-AFL clinical trial.
The iCMR lab at CHUV will serve as a European Centre of Excellence for training physicians on real-time cardiac ablation procedures.
Imricor Medical Systems (ASX:IMR) has completed its first atrial flutter ablation procedure using its innovative iCMR (interventional cardiac magnetic resonance) technology at Lausanne University Hospital (CHUV) in Switzerland. This marks an important milestone for the company, as CHUV becomes its first customer site in Switzerland and the third active site in the VISABL-AFL clinical trial, which supports US FDA approval for Imricor's products.
The iCMR lab at CHUV is a state-of-the-art facility dedicated to performing real-time cardiac ablations using magnetic resonance imaging (MRI), a breakthrough in the field of electrophysiology. Unlike traditional procedures that rely on x-ray fluoroscopy, iCMR uses MRI for superior imaging, allowing for faster, safer, and more effective treatment of cardiac arrhythmias, especially in visualizing the heart and vascular structures that are often invisible to x-rays.
CHUV joins Johns Hopkins Hospital in the USA and the Cardiovascular Institute of South Paris in France in enrolling patients for the VISABL-AFL trial. The CHUV site, which recently completed the construction of a cardiology-owned iCMR lab specifically designed for Imricor’s procedures, will also serve as one of the company’s European Centres of Excellence. This centre will play a key role in advancing the technology, providing training for physicians from other hospitals to perform iCMR cardiac ablations and other interventions as the number of active sites across Europe continues to grow.
Imricor's iCMR technology is unique in that it is the only MRI-compatible platform available for conducting cardiac ablation procedures, with consumables such as single-use ablation catheters that are essential for the technique. The company is positioning itself as a leader in this emerging field, with the potential to revolutionize cardiac care through its advanced imaging and interventional capabilities.
